Industry/Agency Revolving Door Hits Spear In Nose, But Firm Relaunches ANDA

While Spear's generic fluorouracil is back on the market after a temporary restraining order expired June 18, the odyssey illustrates the risks to companies inherent in FDA relying on industry opinions during product review